Buscar
Mostrando ítems 1-10 de 716
Ticagrelor vs Clopidogrel After Fibrinolytic Therapy in Patients With ST-Elevation Myocardial Infarction: A Randomized Clinical Trial
(American Medical Association, 2018)
Importance: The bleeding safety of ticagrelor in patients with ST-elevation myocardial infarction treated with fibrinolytic therapy remains uncertain. Objective: To evaluate the short-term safety of ticagrelor when compared ...
Primary Joint Arthroplasty Surgery: Is the Risk of Major Bleeding Higher in Elderly Patients? A Retrospective Cohort Study
Background Increased risk of bleeding after major orthopedic surgery (MOS) has been widely documented in general population. However, this complication has not been studied in elderly patients. The purpose of this study ...
Major bleeding risk assessment in atrial fibrillation patients taking vitamin K antagonists
(HCPA/FAMED/UFRGS, 2015)
Hepatic bleeding induced by streptokinase and heparin in a patient with acute myocardial infarction
(2002-12-01)
Although rare, major bleeding is the most important side effect of thrombolytic therapy in acute myocardial infarction (AMI) (Levine et al., 1995). Spontaneous hepatic bleeding in normal liver after thrombolytic administration ...
Hepatic bleeding induced by streptokinase and heparin in a patient with acute myocardial infarction
(2002-12-01)
Although rare, major bleeding is the most important side effect of thrombolytic therapy in acute myocardial infarction (AMI) (Levine et al., 1995). Spontaneous hepatic bleeding in normal liver after thrombolytic administration ...
Aspectos endoscópicos no manejo da úlcera péptica gastroduodenal
(Colégio Brasileiro de Cirurgiões, 2008)
Bleeding remains a common and a potential lethal complication for peptic ulcer disease. Multidisciplinary approach by endoscopists, surgeons and intensive care physicians is necessary to improve results for this severe ...
Risk of Early Bleeding with Dual Antiplatelet Therapy in Acute Stroke and Transient Ischemic Attack Regardless of NIHSS Admission.
(2021-05-01)
Background: Dual antiplatelet therapy (DAT) is a therapeutic option for patients with minor ischemic stroke (IS) or transient ischemic attack (TIA). No study has evaluated the incidence of early bleeding in patients with ...
Von Willebrand factor (VWF) as a risk factor for bleeding and thrombosis
(Maney Publishing, 2012-04)
The von Willebrand factor (VWF) is analysed as a bleeding and thrombotic risk marker. When the VWF level is increased, it predicts a thrombotic phenotype and when VWF level is low in plasma, the phenotype varies to bleeding ...